Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.51 |
| ▸ | ACE | P12821 | 3/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 8/20 | 0.32 |
| ▸ | CTSG | P08311 | 3/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626378 | 0.77 | FAAH (0.43) | FAAHELANECTSG | |
| SCHEMBL3226035 | 0.77 | ACE (0.39) | FAAHACE | |
| SCHEMBL169033 | 0.77 | CYP3A4 (0.44) | FAAHACENOS1NOS2MEN1 | |
| SCHEMBL5691751 | 0.77 | FAAH (0.34) | FAAHMGLL | |
| SCHEMBL28017368 | 0.75 | ACE (0.38) | FAAHACEKMT2A | |
| SCHEMBL1645972 | 0.73 | FAAH (0.40) | FAAHNOS1NOS2MEN1ALDH1A1 | |
| SCHEMBL360776 | 0.73 | FAAH (0.40) | FAAHNOS1NOS2MEN1ALDH1A1 | |
| SCHEMBL6338204 | 0.72 | ELANE (0.38) | FAAHACEMEN1ALDH1A1KMT2A | |
| SCHEMBL26361631 | 0.71 | FAAH (0.39) | FAAHACENOS1NOS2MEN1 | |
| SCHEMBL27742564 | 0.71 | ACE (0.35) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169240-B2 | Ketone linked benzothiazole inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150239879-A1 | KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-27 | — | — | US | disclosed |
| EP-2895483-A1 | KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | Bristol-Myers Squibb Company (US) | 2015-07-22 | — | — | EP | disclosed |
| WO-2014042939-A1 | KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-20 | — | — | WO | disclosed |
| JP-2007284648-A | METHOD FOR TREATING POLYVINYL BUTYRAL RESIN AS INTERLAYER FILM OF AUTOMOBILE GLASS LAMINATE | RAKU:KK | 2007-11-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239879-A1 | KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, LIPE | FAAH 176/4885ACE 140/4885NOS1 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.